Pharmacyte Biotech Inc. (OTCMKTS:PMCB) Gets Another Pump

Pharmacyte Biotech Inc. (OTCMKTS:PMCB) managed to add 21.74% to its market value yesterday, after another round of paid pumps targeting it hit inboxes.

Goldman Small Cap Research had a lot of positive things to say about Pharmacyte in its “report”. As is to be expected in such cases, the analyst presented a pretty one-sided picture of PMCB. What is truly surprising is the fact that this time, the commenter made a small effort at presenting investors with meaningful information, at the end of the report, warning investors that the ticker is volatile and they should be on the look out.

Warning of a stock’s volatility while being the biggest cause of volatility around can be seen as somewhat hypocritical, but we’ll leave possible debates on this particular matter for another time.

A detail that deserves more attention presently is the fact that the company fancies itself an active business and claims to aspire to greatness, while being targeted by paid pumps. It doesn’t take a genius to see the contradiction in this situation.

And while it is entirely possible that PMCB may create serious investor value for its supporters at some time in the future, that will only happen if its science checks out and it receives all the necessary permits from the FDA and the appropriate authorities overseeing the overseas drug markets. Seeing as how it is yet to enter even Phase 2b of its clinical trials, investors, no matter how dedicated they are, should probably not hold their breath waiting for that to happen.

Meanwhile, opportunistic traders wishing to make money out of PMCB had better be on their toes, because the fact that it is currently being pumped means that its charts will most probably turn ugly before too long, in spite of any potential it may hold for the far future.